Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olala Trial: Characterization of Long-Term Responders on Olaparib in Solid Tumours
2017-002808-28Phase 4Active
- Sponsor
- Princess Margaret Cancer Centre
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of olaparib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more, sponsored by Princess Margaret Cancer Centre. Primary endpoint: Clinical, molecular, and genomic characterization of disease control on olaparib. Started Oct 2017; status: active.
02
Drugs
olaparib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2017-002808-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002808-28.